Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
- 1 December 1997
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 350 (9093), 1729-1733
- https://doi.org/10.1016/s0140-6736(97)05535-9
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTSTransplantation, 1996
- OKT3 Treatment for Allograft Rejection Is a Risk Factor for Cytomegalovirus Disease in Liver TransplantationThe Journal of Infectious Diseases, 1995
- High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver Transplant RecipientsAnnals of Internal Medicine, 1994
- Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysisJournal of Hepatology, 1993
- Cytomegalovirus Immune Globulin Prophylaxis in Liver TransplantationAnnals of Internal Medicine, 1993
- THE COST IMPACT OF CYTOMEGALOVIRUS DISEASE IN RENAL TRANSPLANT RECIPIENTSTransplantation, 1993
- Donated organ as a source of cytomegalovirus in orthotopic liver transplantationJournal of Medical Virology, 1992
- Clinical Patterns of Cytomegalovirus Disease After Liver TransplantationArchives of Surgery, 1989
- CYTOMEGALOVIRUS INFECTION AND DONOR/RECIPIENT HLA ANTIGENS: INTERDEPENDENT CO-FACTORS IN PATHOGENESIS OF VANISHING BILEDUCT SYNDROME AFTER LIVER TRANSPLANTATIONThe Lancet, 1988
- Infections with Cytomegalovirus and Other Herpesviruses in 121 Liver Transplant Recipients: Transmission by Donated Organ and the Effect of OKT3 AntibodiesThe Journal of Infectious Diseases, 1988